Moderna And Merck Say Their mRNA Cancer Vaccine Cut Death, Recurrence By 42%

TL;DR

Before you orderOffer from Amazon

Get workout gear delivered free with Prime

• Fast, free delivery on millions of items
• Prime Video, Amazon Music and more included
• Member-only deals all year

Start your free Prime trial →Free trial for eligible customers · Cancel anytime

As an affiliate, we earn on qualifying purchases.Hide

Moderna and Merck reported that their personalized mRNA vaccine, intismeran, combined with Keytruda was associated with a 42% lower risk of melanoma recurrence or death than Keytruda plus placebo after surgery. At two years, 82% of patients in the vaccine group were alive without recurrence, compared with 70% in the comparison group; the companies’ announcement does not provide all details needed to assess the results independently.

Moderna and Merck said a Phase 3 trial found that their personalized mRNA cancer vaccine, intismeran (mRNA-4157), combined with Keytruda was linked to a 42% lower risk of melanoma recurrence or death than Keytruda plus placebo. At two years, 82% of patients receiving the vaccine combination were alive without recurrence, compared with 70% in the comparison group.

The trial studied patients with resected melanoma who received Keytruda, also known as pembrolizumab, alongside either intismeran or a placebo. The companies reported the primary outcome as recurrence-free survival, or RFS: the time patients remained alive without their cancer returning. The reported 42% figure is a relative reduction in risk compared with the Keytruda-placebo group, not a 42-percentage-point difference in the share of patients who remained recurrence-free.

For distant metastasis-free survival, which tracks time alive without cancer returning in a different part of the body, the combination was associated with a 38% lower risk of distant metastasis or death. At the reported assessment, 88.5% of patients in the intismeran group were alive without distant metastasis, compared with 80% of those given Keytruda and placebo. The companies’ announcement, as described in the source report, did not supply full trial data or detailed statistical information.

Intismeran is designed for each patient. Researchers compare genetic sequences from a person’s tumor and healthy cells to identify tumor-specific mutations, then make a synthetic mRNA vaccine encoding up to 34 selected mutations. The goal is to prompt an immune response directed at cancer cells carrying those mutations. The vaccine was tested as an addition to Keytruda, not as a replacement for it.

A Possible Addition After Melanoma Surgery

The findings matter because patients whose melanoma has been surgically removed may still face a risk that the disease returns or spreads. The reported results suggest that a personalized vaccine could add benefit to Keytruda, an existing standard treatment, in this post-surgery setting. The difference in two-year recurrence-free outcomes—82% versus 70%—gives a more direct picture of the groups’ results than the relative-risk figure alone.

However, these results do not show that the vaccine cures melanoma, nor do they establish how long the benefit lasts. The reported outcomes are for the trial population and follow-up period; they do not predict an individual patient’s result. The findings also concern melanoma and this particular treatment combination, not mRNA cancer vaccines generally. Patients should discuss treatment choices with their oncology team rather than infer that the vaccine is available or appropriate for them.

How the Personalized Vaccine Was Tested

The study compared intismeran plus Keytruda with Keytruda plus placebo in people with melanoma that had been removed surgically. RFS measures time alive without any recurrence; DMFS measures time alive without the cancer appearing at a distant site. Both measures include death as an event in the risk figures reported by the companies.

The reported two-year results are less pronounced than those in an earlier Phase 2 study with five-year follow-up. That study showed a 49% reduction in recurrence-or-death risk and a 59% reduction in distant-metastasis-or-death risk, according to the source report. Results from different trial phases and follow-up periods are not directly interchangeable, and the figures do not by themselves explain why the estimates differ.

“The trial “is the first Phase 3 study to demonstrate a clinically meaningful improvement in RFS and DMFS over standard-of-care KEYTRUDA in patients with resected melanoma.””

— Dean Li, president of Merck Research Laboratories

Full Trial Data Still Needed

The available account is based on a company announcement and does not include the full Phase 3 results. It is not yet clear from the supplied material how many people took part, the exact statistical uncertainty around the estimates, the trial’s detailed safety findings, or how outcomes varied among patient groups. Those details are needed to judge the strength and limits of the reported benefit.

The announcement also does not establish whether regulators have approved intismeran for melanoma, when any regulatory filing might occur, or whether the vaccine will be available outside a clinical trial. The reported figures cover an approximately two-year outcome period; longer follow-up will be needed to determine whether the differences persist.

Publication and Longer Follow-Up

Further scrutiny will depend on the complete Phase 3 data, including safety results, statistical analyses and details about the patients studied. The source material does not specify when the findings will be published in a peer-reviewed journal or whether the companies have announced a regulatory submission timetable.

Longer follow-up should clarify whether the reported gains in recurrence-free and distant metastasis-free survival continue over time. Until full results and any regulatory decisions are available, the announcement is evidence of a reported trial benefit—not confirmation that intismeran is an approved treatment option.

Key Questions

What did the trial report?

Moderna and Merck said intismeran plus Keytruda was associated with a 42% lower risk of recurrence or death than Keytruda plus placebo in patients with surgically removed melanoma. The companies also reported a 38% lower risk of distant metastasis or death.

Does 42% mean 42% more patients avoided recurrence?

No. The 42% figure describes a relative reduction in risk, not a 42-percentage-point difference in patient outcomes. At two years, 82% of the vaccine-combination group and 70% of the comparison group were alive without recurrence.

What is intismeran?

Intismeran, also called mRNA-4157, is a personalized mRNA vaccine designed around selected mutations in a patient’s tumor. In the trial it was given with Keytruda, rather than tested as a stand-alone replacement.

Is the vaccine approved for melanoma?

The supplied report does not say that intismeran has received regulatory approval or provide a filing timetable. Its availability and status remain unclear from the announcement details provided.

What information is still missing?

The full trial report is needed for details such as participant numbers, statistical uncertainty, safety results and outcomes across patient groups. Longer follow-up will also show whether the reported differences persist beyond two years.

Source: hn